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Abstract
Background: Irritable Bowel Syndrome (IBS) is a common gastro-intestinal disorder in primary and secondary care,
characterised by abdominal pain, discomfort, altered bowel habits and/or symptoms of bloating and distension. In
general the efficacy of drug therapies is poor. Hypnotherapy as well as Cognitive Behaviour Therapy and short
Psychodynamic Therapy appear to be useful options for patients with refractory IBS in secondary care and are cost-
effective, but the evidence is still limited. The IMAGINE-study is therefore designed to assess the overall benefit of
hypnotherapy in IBS as well as comparing the efficacy of individual versus group hypnotherapy in treating this
condition.
Methods/Design: The design is a randomised placebo-controlled trial. The study group consists of 354 primary
care and secondary care patients (aged 18-65) with IBS (Rome-III criteria). Patients will be randomly allocated to
either 6 sessions of individual hypnotherapy, 6 sessions of group hypnotherapy or 6 sessions of educational
supportive therapy in a group (placebo), with a follow up of 9 months post treatment for all patients. Ten hospitals
and four primary care psychological practices in different parts of The Netherlands will collaborate in this study.
The primary efficacy parameter is the responder rate for adequate relief of IBS symptoms. Secondary efficacy
parameters are changes in the IBS symptom severity, quality of life, cognitions, psychological complaints, self-
efficacy as well as direct and indirect costs of the condition. Hypnotherapy is expected to be more effective than
the control therapy, and group hypnotherapy is expected not to be inferior to individual hypnotherapy.
Discussion: If hypnotherapy is effective and if there is no difference in efficacy between individual and group
hypnotherapy, this group form of treatment could be offered to more IBS patients, at lower costs.
Trial registration number: ISRCTN: ISRCTN22888906
Background
Irritable bowel syndrome (IBS) is a chronic functional
gastrointestinal disorder, characterised by recurrent epi-
sodes of abdominal pain, discomfort, altered bowel
habits and/or symptoms of bloating and distension, not
explained by structural or biochemical abnormalities [1].
The estimated prevalence is 14-24% for women and 5-
19% for men [2]. The consultation rate is relatively low:
only 20-25% of IBS patients seek medical advice [3] but
because the prevalence is so high this still represents a
substantial number of patients. The reported incidence
of IBS in primary care is 4-13/1000 patients a year [4].
General Practitioners see on average 1-2 new IBS
patients a week. In the Netherlands about 10% of the
patients seen by a GP are referred to a medical specia-
list, i.e. gastroenterologists [5], in UK 44% [1]. The esti-
mated number of patients, who are diagnosed with IBS
after referral to the gastroenterologists, varies from 20-
70% [6]. Patients with IBS can have severe and often
incapacitating complaints, resulting in as much annual
absence from work as, for instance, from the flu [7].
T h ed i a g n o s i sc a no n l yb ec o n s i d e r e di ft h e r ea r en o
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now consensus based criteria, the most recent of which
are the so called Rome III criteria [8]:
Irritable Bowel Syndrome
Diagnostic criterion*
Recurrent abdominal pain or discomfort** at least 3
days/month in the last 3 months associated with two or
more of the following:
Improvement with defecation
Onset associated with a change in frequency of stool
Onset associated with a change in form (appearance)
of stool
* Criterion fulfilled for the last 3 months with symp-
tom onset at least 6 months prior to diagnosis
** “Discomfort” means an uncomfortable sensation not
described as pain.
In pathophysiology research and clinical trials, a pain/
discomfort frequency of at least 2 days a week during
screening evaluation is recommended for subject
eligibility
Three types of IBS can be distinguished: IBS with
either predominant constipation, predominant diarrhoea,
or alternating periods of diarrhoea and constipation.
Several pathophysiological mechanisms underlying IBS
have been proposed, including a disturbance in intest-
inal motility and enhanced visceral sensitivity which,
according to the bio-psycho-social model of IBS, interact
with other factors such as environmental influences,
parent-child interactions and disturbed stress responses
to result in symptoms [9].
Effective therapy of IBS is lacking. A recent review on
pharmacological treatment for IBS [10] concluded that
in general the efficacy of drug therapies is poor. Bulking
agents, antispasmodics, and antidepressants can be tried
but the response is often suboptimal.
Since 1984 [11] there has been an increasing research
interest on the effectiveness of psychological treatment
for IBS. A wide range of psychotherapeutic interventions
have been studied including: relaxation therapy, biofeed-
back, cognitive behavioural therapy (CBT), short psycho-
dynamic therapy and hypnotherapy. Two Cochrane
reviews on the efficacy of hypnotherapy [2] and other
psychological therapies [12] support effectiveness. In
England the NICE guideline (2008) on IBS was pub-
lished, with a special section on the psychological inter-
ventions which concluded that “CBT as well as short
Psychodynamic and Hypnotherapy can be a useful
option for patients with refractory IBS” [13]. Hypnosis is
officially recognised as a legitimate medical treatment by
the British Medical Association (1955) and the Ameri-
can Medical Association (1958). There has been much
research on the use of hypnosis in the treatment of
(chronic) pain [14] and, as pain is the main symptom of
IBS, it is understandable that therapists have applied
hypnosis in treatment of IBS patients. Pooled results of
research about the effectiveness of hypnotherapy for
IBS-patients are described in three reviews/meta-analy-
sis. The NICE guideline [13] concludes that hypnother-
apy may be considered a promising intervention for IBS,
but judges the evidence as still too limited. Further
investigation is recommended, with special interest in
the potential of this intervention as a primary care ther-
apy option, with long term follow-up. The Cochrane
review on hypnotherapy for treatment of IBS concludes
that “The quality of the included trials was inadequate
to allow any conclusion about the efficacy of hypnother-
apy for irritable bowel syndrome.” And, “More research
with high quality trials is needed” [2].
In a more recent meta-analysis Ford et al. conclude
that hypnotherapy leads to less persistence of com-
plaints than usual care or control therapy [15].
On the basis of these publications one can conclude
that hypnotherapy is a promising and possibly cost-
effective intervention for IBS in secondary care. Further
investigation with high quality trials and long term fol-
low up is needed, especially with regard to its efficacy in
a primary care setting.
To improve cost effectiveness, group application of
hypnotherapy could be considered. So far, there has
only been one study on a group application [16], indi-
cating no significant difference in effectiveness in a
population of only 33 patients.
We have designed a RCT, comparing the effectiveness
and costs of individual and group hypnotherapy with a
control intervention in patients with IBS. In this paper,
we describe the aim, design and methodological chal-
lenges of the study protocol.
Methods/Design
Aims
The primary objectives of this study are two-fold. The
first aim is to assess the efficacy of hypnotherapy in IBS
treatment. The second goal is to compare the efficacy of
group hypnotherapy with individual hypnotherapy in
IBS treatment. Secondary objectives are to assess the
effect of individual or group hypnotherapy on symptom
severity, on quality of life, dysfunctional cognitions, psy-
chological complaints, self-efficacy, and IBS related
costs.
Design
The study is designed as a comparative and a non-infer-
iority 12-weeks single blind controlled parallel-group
trial. The trial will involve IBS patients in primary and
secondary care, who will be randomly allocated to either
6 sessions of individual hypnotherapy, 6 sessions of hyp-
notherapy in group format, or 6 sessions of educational
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(Flowchart Figure 1). Starting May 2011, the inclusion of
patients will take approximately two years, with a fol-
low-up of nine months.
Ethical considerations
The study is conducted according to the principles of
the Declaration of Helsinki and in accordance with the
Medical Research Involving Human Subjects Act
Study population
Intake procedure: in/excl: 
informed cons.
Referral of patients
18-65 years, Rome III
Outcome measurement
directly after treatment
Drop-out:
Outcome measurement
directly after treatment
Outcome measurement
directly after treatment
Drop-out:
Drop-out:
Follow-up measurement 
after 9 months
Follow-up measurement 
after 9 months
Drop-out:
Drop-out: Drop-out:
Follow-up measurement 
after 9 months
Hypnotherapy in a group Individual hypnotherapy
Drop-out: Drop-out: Drop-out:
Drop-out: excl. criteria; no 
informed  cons.
Baseline outcome 
measurement
Randomisation
Educational-supportive th. 
In a group
Drop-out:
Drop-out:
Figure 1 Design of the RCT.
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Medical Ethics Committee of the University Medical
Centre of Utrecht, the Netherlands.
Patient data will be coded and analysing and publica-
tion of the results will be anonymous.
Hypotheses
The primary hypotheses assessed in this study are:
At the end of therapy, more patients in the hyp-
notherapy condition will report adequate relief than in
the educational supportive therapy condition (control
treatment).
Hypnotherapy offered in a group format is as effective
as individual hypnotherapy.
Study population
The study population consists of patients with IBS
referred by GP or medical specialist. Ten general hospi-
tals and four psychological practices in primary care col-
laborate in the study.
Inclusion criteria
Age 18-65 years
diagnosis of IBS according to the Rome III criteria.
The Dutch translated version of the IBS Module of the
Rome Foundation [8] is used to check criteria.
Exclusion criteria
inability to understand the content of the sessions,
because of insufficient command of the Dutch language.
inability to fill out the questionnaires.
inability (for example: too aggressive) or unwillingness
to function in a group.
a psychiatric condition that requires attention first (for
example severe depression, PTSS or psychosis).
a combination of IBS and other chronic bowel dis-
eases, as far as they already diagnosed, such as ulcerative
colitis, Crohn’s disease or coeliac disease.
major surgery to the lower gastrointestinal tract, such
as partial or total colectomy, small bowel resection or
partial or total gastrectomy.
past or present radiotherapy to the abdomen (eg carci-
noma of the cervix).
Procedure
Cooperating GPs and specialists are asked to give each
eligible patient an invitational letter explaining the goal
of the study and describing the interventions. The patient
fills in the IBS questionnaire to confirm the diagnosis. If
the patient is interested in participating in the trial, the
GP or specialist hands the patient study information with
the Informed Consent letter and a brochure from the
government explaining the law and the rights of patients
participating in medical research. After confirmation of
the intention to participate, the patient is referred to the
collaborating psychologist, either in the hospital or in
primary care practice. The psychologist checks the in-
and exclusion criteria and explains the study. If the
patient is willing to participate, she/he signs the Informed
Consent letter, completes the questionnaires and sends
them, together with the IBS-criteria checklist in a reply-
envelope to the investigator. After randomisation the
patient is invited to the therapy she/he is randomised to.
Randomisation
After inclusion, patients are randomly allocated to one
of the three treatment conditions by means of a compu-
ter-based, six-block random number tables procedure.
Because for group treatment six patients are required,
the randomisation is done block-wise to prevent pro-
longed waiting time for the individual patient. The
researcher performs randomisation.
Intervention
Patients will be randomised to one of the three treat-
ment arms.
(a) Individual hypnotherapy is delivered in a series of
6 individual, bi-weekly 45-minute sessions in which
patients receive a structured hypnotherapy treatment.
The treatment procedure is developed by the investiga-
tor (C.F.) based on the hypnotherapy protocol for IBS
from the research group of Whorwell in Manchester UK
[17]. Basically, hypnotic suggestions are given to normal-
ise motility of the gut and reduce pain and feelings of
discomfort. The precise wording is adjusted to the indi-
vidual patient. Treatment is given by qualified psycholo-
gists who are educated as hypnotherapists and
specifically trained for the intervention.
(b) Group hypnotherapy is delivered in a series of 6
bi-weekly 60-minute group sessions, with a maximum of
6 IBS patients per group. The group hypnotherapy is
based on the same principle as the individual hyp-
notherapy but is adapted for the group format. Group
hypnotherapy will be given by the same psychologists
who deliver the individual therapy.
Both individual and group hypnotherapy patients are
given homework assignments consisting of CD recorded
hypnotherapeutic exercises. Carrying out these exercises
takes 15-20 minutes, at least once daily.
(c) Educational supportive therapy is delivered in a ser-
ies of 6 bi-weekly 60-minute group sessions, with a maxi-
mum of 6 patients per group. In the sessions topics are
discussed that are of importance to IBS patients, as deter-
mined by research [18-22]. The topics include: informa-
tion about IBS; the role of food and life-regulation and
dealing with stress in managing IBS. Homework assign-
ments are given that take about 15-20 minutes per day.
Educational supportive therapy will be performed by
nurse practitioners or psychological assistants who are
specifically trained for the intervention.
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therapy protocol in which all sessions are described
(verbatim). Therapists receive this verbatim protocol,
the CD with the hypnotherapeutic exercises and home-
work assignments.
All therapists are trained in the protocol they carry
out and subsequent treatment is supervised by the prin-
cipal researcher.
To prevent contamination of groups, therapists giving
hypnotherapy will not give educational supportive ther-
apy and vice versa.
Other treatments during the study
Patients may continue usual care as instructed by their
physicians but are asked not to change it during the
research, except on doctor’s advice. They are free to
seek other treatment. This will be recorded in their
questionnaire.
Study parameters/endpoints
As yet, it is not known what makes hypnotherapy an
effective treatment. We assume that hypnotherapy has a
direct influence on visceral hypersensitivity (pain proces-
sing and pain perception [14] and an indirect influence
on pain perception through relaxation and changing
cognitions. Furthermore, gut motor activity (motility)
can be influenced by hypnotherapy [14]. Finally, hyp-
notherapy can have an effect on psychological factors
such as self-efficacy and feelings of depression that can
play a role in IBS. Our choice for outcome measures
has been influenced by these assumptions.
Main study parameter/endpoint
In line with previous conclusions on optimal outcome
assessment in trials on functional gastrointestinal disease
[23,24], we chose the number of weeks with adequate
symptom relief as the primary outcome. This measure
addresses weekly symptom improvement in IBS with
treatment using a single question ("Did you have ade-
quate relief of IBS-related abdominal pain or discomfort
in the past week?”) scored on a dichotomous scale (Yes/
No). This instrument is a well validated simple outcome
assessment for IBS treatment [25] with a positive
responder being defined as someone with more than 2
weeks adequate relief per month [26] which has deter-
mined to indicate a clinically significant improvement
[26].
The first primary outcome is the difference in the per-
centage of positive responders between group hyp-
notherapy and group educational therapy. Group
hypnotherapy is expected to be substantially more effec-
tive than educational therapy.
The second primary outcome is the difference in per-
centage of positive responders between group hyp-
notherapy and individual hypnotherapy. Group
hypnotherapy is expected not to be inferior to individual
hypnotherapy.
Secondary study parameters/endpoints
Irritable Bowel Syndrome Symptom Severity IBS
symptoms will be monitored using the IBS symptom
severity score (IBS-SSS).
The IBS-SSS assesses five features of IBS (pain severity
and frequency; abdominal distension; bowel satisfaction;
interference with life in general) and their intensity,
using visual analogue scales [27]. The IBS-SSS has been
validated and its use is recommended in an overview on
outcome measures [24].
Irritable Bowel Syndrome Quality of Life Disease-spe-
c i f i cq u a l i t yo fl i f ew i l lb ea s s e s s e du s i n gt h eI r r i t a b l e
Bowel Syndrome Quality of Life scale (IBS QOL) [28]. It
has been validated in different populations. This instru-
ment includes 30 items and consists of nine scales (dys-
phoria; interference with activity; body image; health
worry; food avoidance; social reaction; sexuality; rela-
tionships; overall scale).
Other measurements
Psychological symptoms Psychological symptoms are
assessed with the Dutch version of the Symptom Check-
list (SCL-90). It was originally published by Derogatis
[29] and translated and validated for the Dutch popula-
tion by Arrindell & Ettema [30] The SCL-90 is a 90-
item multidimensional self-report inventory, designed to
evaluate a broad range of psychological problems and
symptoms of psychopathology. It has 9 subscales: Agor-
aphobia, Anxiety, Depression, Somatisation, Insufficiency
of thought and action, Distrust and Interpersonal Sensi-
tivity, Hostility, Sleeping problems and Psychoneuroti-
cism (total score).
The SCL-90 is an internationally accepted, widely
used, questionnaire with good psychometric qualities
[29].
Dysfunctional cognitions The Cognitive Scale for Func-
tional Bowel Disorders (CS-FBD) has been developed by
Toner [31] and translated with permission from the
author by van Rood. The CS-FBD consists of 31 items
to measure a patient’s level of dysfunctional cognitions
concerning his or her IBS. It is a valid and reliable scale
that can be used as an outcome measure in evaluating
the efficacy of psychotherapeutic interventions for func-
tional bowel disorders [31].
Self-efficacy The Self-Efficacy Scale (SES) is a seven-
item questionnaire to measure the confidence of
patients about their capacity to influence their somatic
complaints. It was originally developed for patients suf-
fering from chronic fatigue [32] and adapted with per-
mission of the author by C.Flik and Y. van Rood for
patients with IBS.
Costs The Trimbos/iMTA Questionnaire (Tic-P) for
costs associated with Psychiatric Illness, measures direct
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past four weeks and indirect non-medical costs due to
productivity loss during the past two weeks[33]. It can
be adapted for other conditions as well and for this
study was adapted for IBS.
Time line and follow-up
Enrolment started May 2011. The inclusion of patients
will take approximately two years. After the active treat-
ment period of 12 weeks, all patients will be followed
for an additional period of 9 months, to assess the sus-
tainability of the effects of the interventions. The pri-
mary outcome will be measured weekly during the first
four weeks after finishing treatment and again weekly
during four weeks 9 months post treatment. The sec-
ondary endpoints will be assessed prior to intervention,
immediately after the intervention and at 9 months after
finishing the intervention.
Other study parameters
Patients are given a “CD use” diary in which they can
record the number of times they used the CD or did the
hypnotherapeutic exercises in the last week. The home-
work assignments in the educational supportive therapy
are not registered separately.
Sample Size Calculation
Assuming an individual hypnotherapy response rate of
57% [2], a maximum acceptable level of difference of
15% between individual and group hypnotherapy, an
a l p h ao f0 . 0 5a n dp o w e r( 1 - b e t a )o f0 . 8 0 ,1 3 5p a t i e n t s
are required in both arms of the non-inferiority trial to
show that group-hypnotherapy is not inferior to indivi-
dual hypnotherapy.
Spiller [34], in an overview of 25 randomised con-
trolled trials, states that when the placebo response is
plotted against the length of study, placebo response
will be maximum of 75% at around 6-8 weeks, falling to
25% at 24 weeks and zero at 12 months. Our follow-up
period will be 9 months. To test whether group hyp-
notherapy is more effective than group placebo therapy,
we will have more than sufficient power assuming a pla-
cebo-response rate of 25% and a group hypnotherapy
response rate of 57% [13] using the proposed 135
patients in both arms. Powering the study for only the
comparison between hypnotherapy and the control
intervention, would require only 44 patients in both
arms assuming an alpha of 0.05, a power (1-beta) of
0.80, a cluster size of 6 patients per therapist and an
intra-class correlation coefficient of 0.05. Assuming at
least 10% of loss to follow-up, 354 patients need to be
included in the study (150+150+54 (placebo-arm)).
Recruitment
The 354 patients are recruited in primary and secondary
care.
Primary care: Assuming an estimated mean incidence
of IBS in primary care in 8 of every 1000 patients, 20
newly diagnosed patients per practice per year and an
expected inclusion rate of 25%, 30 general practitioners,
Table 1 Overview of assessments.
Weeks
Visit
(time point)
0
(start of
treatment)
12
(end of
treatment)
12+
Every 4 week
(end of treatment + 4
weeks)
12+
Every week
After
treatment
52
(9 months after
treatment)
52 + 4
(4 weeks after 9
months)
Assessments
IBS-Mode X X
Informed consent X
Inclusion exclusion
criteria
X
Demographic data X
Status report X
Adequate relief X X
IBS-SSS X X X
IBS-QOL X X X
SCL-90 X X X
CS-FBD X X X
SES X X X
TiC-P X X X
CD-diary X X
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the total required number of patients (354) in 2,5 years.
Secondary care: The estimation of the number of con-
sultations for IBS in gastroenterology practice, varies
between 20-70% of all referrals per year. Using a conser-
vative estimate, about 25% of all referrals will be because
of IBS. Thus, in a normal gastroenterologist’s practice of
a general hospital, with 500 new patients for each gas-
troenterologist each year, there will be 125 new IBS
patients each year. Assuming that 10% of the patients
will be interested in taking part in the trial, each gastro-
enterologist can refer 12 patients a year. Therefore 10
hospitals with at least 2 referring specialists to cooperate
in this study for 1,5 years (354 patients) are needed.
Ten hospitals and four primary care psychological
practices (working with several referring GPs), in differ-
ent parts of the Netherlands, have agreed to collaborate
in the trial. This ensures that the study population will
be representative of the whole Dutch population.
When combining the expected referral rates from the
primary and secondary care practices, two years of
recruitment will be sufficient to attain the required
number (354) of participants.
Statistical analysis
General remarks
All statistical analyses will be based on the intention-to-
treat principle, i.e. patients will be analysed according to
their initial assignment to one of the randomisation
arms.
Uni- & bivariate analysis
The percentage of patients with a positive response will
be calculated post-treatment and at 9 months after
treatment and differences between the three randomisa-
tion arms will be tested with the chi-square test.
In addition, the adequate relief scores and secondary
outcomes (IBS- SSS, IBS-QoL, SCL-90-, CS- FBD-, SES-
and TiC-P scores) will be estimated by time point of
assessment and arm of randomisation using a statistical
model for repeated measurements (preferably a random
effects model). To assess the difference between the
arms of randomisation by time point of assessment,
terms for interaction of {arm × time point} will be
included in the statistical model.
Multivariate analysis
Subgroup analyses The analyses described above will
also be performed separately for patients who fulfil the
Rome III IBS diagnostic criteria for constipation-predo-
minant, diarrhoea-predominant and mixed type IBS. In a
study of Gonsakorale et al [35] one of the conclusions
was that hypnotherapy was less useful for males with
diarrhoea. If males with diarrhoea-predominant bowel
habit are over-represented in one of the conditions,
adjustment in multivariate regression analysis is indicated.
Analyses will be performed separately for those
referred from primary and secondary health care. In sec-
ondary care, IBS-patients have a longer disease history,
more psychosocial co-morbidity and higher stress and
depression scores. It is possible that these differences
may influence the effect of the intervention.
Adjustment for confounders
In case of (unexpected) differences in relevant baseline
characteristics between thet h r e ec o m p a r i s o ng r o u p s ,
adjustment for the possible confounding effect of these
differences will be performed in multivariate regression
analyses.
Risk/Benefit for patients
Benefit: Research indicates that hypnotherapy is a pro-
mising intervention for IBS which could potentially be
of considerable benefit to the patients participating in
the study. Research also indicates that patients want to
be informed more about IBS. Patients randomised to
the placebo condition receive this information and thus
can also benefit from participating in the study.
Risk: In all the research that has been evaluated by the
Cochrane study, no adverse effects for patients have
been reported. This treatment is symptom-oriented with
care taken to exclude those individuals with contra-indi-
cations and treatment is always carried out by experi-
enced therapists educated in hypnotherapy.
Discussion; Methodological challenges
In planning this study, a number of challenges com-
monly encountered in studies on functional GI diseases
needed to be overcome: selection of the study popula-
tion; diagnostic inclusion criteria; a valid control inter-
vention; placebo effect and outcome assessment.
Selection of the study population
Lack of heterogeneity among IBS patients can affect the
generalisability of trial results [36]. To overcome this
problem, patients will be recruited from primary and
secondary care populations. The NICE guideline (2008)
recommends the inclusion of patients from primary care
to enhance the generalisability of the results. Co-operat-
ing hospitals and primary care practices are situated all
over Holland, so the population participating in the
s t u d yw i l lb er e p r e s e n t a t i v eo ft h ew h o l eD u t c h
population.
Although attention to the study was drawn by
announcements to both physicians in primary and sec-
ondary care and patients by the Dutch IBS Patient
Foundation web-site, there will always be a selection
bias, because only patients who are motivated are
included in this study. It cannot be ruled out that they
differ in some respects from those who do not want to
participate on the effect of hypnotherapy.
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The selection of the diagnostic inclusion criteria were a
second challenge in the study. A task force of the Amer-
ican Journal of Gastroenterology [37] conducted a sys-
tematic review on the accuracy of symptom-based
criteria in the diagnosis of IBS. They summarise the
diagnostic criteria that have been used over the years
which are those reported by: Manning (1978); Kruis
(1984) Rome I (1990); Rome II (1999) Rome III (2006).
The main differences are in the number of symptoms
included as well as their duration which is important as
they should be been present for a considerable period of
time before the diagnosis is considered.
The accuracy of the Rome II and III criteria has not
been formally evaluated yet and the ACG task force
chose their own pragmatic definition: “abdominal pain
or discomfort that occurs in association with altered
bowel habits over a period of at least three months”.
Because of the problem of the absence of a specific
diagnostic test for IBS, the Rome committee developed
t h eI B S - m o d u l e ,as h o r tq u e s tionnaire (10 questions)
with a scoring device. It is applicable in primary and
secondary care and takes only a few minutes for patients
to complete. For standardisation and to facilitate com-
p a r i s o no fr e s e a r c hp o p u l a t i o n si nt h ef u t u r e ,i nt h i s
RCT the questionnaire was chosen to confirm the diag-
nosis of IBS.
The Rome committee has started a translation project
to make it possible for this questionnaire to be used
worldwide. Following official translation guidelines [38]
and with the official consent of the Rome III committee,
the module has been translated into Dutch and will be
of use to every specialist in the field of IBS in the
Netherlands.
Optimal control intervention
To design a good control intervention is notoriously dif-
ficult in research on the effectiveness of psychological
treatments [39]. “Care as usual “is not a good control-
option since it does not exclude the possibility that
treatment effect is due to differences in therapist atten-
tion rather than to the intervention [23]. A good pla-
cebo condition needs to have all components of the
experimental intervention, except the active component.
This is very difficult to realise with psychotherapeutic
interventions. A “sham” intervention with the same time
investment for patient and therapist but with a non
therapeutic intervention, potentially generates a negative
effect. Consequently, an intervention was designed in
which hypnotherapy was missing but all other compo-
nents were retained: time, attention, active intervention
and contact with therapist. The intervention, an infor-
mative educational programme, covers topics IBS
patients like to have more knowledge about [18-22].
The informative educational programme will be given
by nurse practitioners or welfare workers and not by
hypnotherapists because it is anticipated that hyp-
notherapists will automatically use the suggestive lan-
guage they use in the hypnotherapy. To emphasise the
supportive and educational character of this control-
intervention, the deliberate use of nurse practitioners or
welfare workers was felt to be the most appropriate to
deliver this intervention. Furthermore, the effects of the
doctor-patient relationship will be controlled for by
using multiple, experienced therapists [39].
Placebo effect
The placebo response causes serious problems for the
design of RCT’s in IBS. Spiller (1999) describes on the
b a s i so f2 5R C T so nm e d i c a t i o na n df i b r ef r o m1 9 7 6 -
1998, a median placebo response of 47% [34]. Ford &
Moayyedi (2010) estimated a response rate of 37.5%
across all RCT’s on pharmacological therapies in adult
IBS-patients [40]. Spiller claims that the placebo
response diminishes after approximately 12 weeks and
was lost altogether by 6 months. Recommendations to
diminish the effect of placebo response on outcomes of
RCT’s are:
Lengths of the therapy should be more than 8 weeks
and follow-up for more than 6 months; diagnosis should
be based on the Rome-criteria and not on clinical jud-
gement; patient-reported endpoints are better than phy-
sician-reported outcomes; it is important to be able to
distinguish between subgroups of IBS-C, IBS-D and
IBS-M.
In the design of this RCT these recommendations
were met in terms of: the length of therapy is 3 months;
follow up will be 9 months after ending the therapy and
we chose for the Rome III IBS-module to diagnose the
cases and distinguish the sub-groups.
Outcome assessment
As no objective standards for diagnosing functional GI-
diseases exist, outcome assessments have to be based on
subjective criteria. According to Irvine [23] the “ade-
quate relief” questionnaire [25] is the current standard
primary outcome measurement in treatment trials of
Functional Gastrointestinal Disorders. For a more
detailed IBS symptom assessment the IBS-Severity Scor-
ing System [27] is recommended [24]. Furthermore, IBS
related Quality of Life is an important secondary out-
come measure [23]. At present, the IBS-Quality of Life
measurement [28] is the best choice, “because it has
been the most extensively validated and shows appropri-
ate psychometric quality” [24]. Mangel, (outcome mea-
sure:"adequate relief “[25]) and Whorwell (IBS-SSS [27])
gave their consent for translating these questionnaires
into Dutch.
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accord with the recommendation on measuring severity
during episodic symptoms by the research design of the
Rome committee [23], patients will fill in the assess-
ments on two occasions: immediately at the end of
treatment and after nine months. Also the ‘adequate
relief’ question is asked every week, for a period of four
weeks.
It is possible that the patients in the control group
with educational supportive therapy also will experience
some improvement in their complaints, but the expecta-
tion is that treatment with hypnotherapy will be
superior.
Conclusion
The results of this primary and secondary care based
randomised placebo controlled trial, evaluating the effi-
cacy of individual and group hypnotherapy treatment in
IBS, will contribute to the scientific basis of IBS man-
agement. The trial intends to include the greatest popu-
lation of patients of all the trials in psychological
treatments for IBS to date [2,12].
If the results of the study show that (group) hyp-
notherapy for IBS is effective, implementation into clini-
cal practice will be the next aim.
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